Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers have made a breakthrough in more precisely targeting drugs to cancers. Using ultrasound and lipid drug carriers (liposomes), a multi-disciplinary team of biomedical engineers, oncologists, radiologists and anaesthetists at the University of Oxford have developed a new way to improve the targeting of cancer drugs to tumours.

None © Celsion
Load More

Meet the lead author of the study

  • Paul Lyon
    Paul Lyon

    Senior Research Fellow in Interventional Oncology

Similar stories

Analysis identifies 50 new genomic regions associated with kidney cancer risk

In a new analysis of genetic susceptibility to kidney cancer, an international team of researchers, including Professor Mark Sullivan from Oxford University's Nuffield Department of Surgical Sciences, has identified 50 new areas across the genome that are associated with the risk of developing kidney cancer.